These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 26910588)

  • 21. Single-dose Intravenous Safety, Tolerability, and Pharmacokinetics and Absolute Bioavailability of LCB01-0371.
    Cho YS; Lim HS; Han S; Yoon SK; Kim H; Cho YL; Nam HS; Bae KS
    Clin Ther; 2019 Jan; 41(1):92-106. PubMed ID: 30559004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.
    Burdette SD; Trotman R
    Clin Infect Dis; 2015 Oct; 61(8):1315-21. PubMed ID: 26105167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers.
    Fang E; Muñoz KA; Prokocimer P
    Am J Ther; 2017; 24(2):e227-e233. PubMed ID: 27941424
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
    Lv X; Alder J; Li L; O'Riordan W; Rybak MJ; Ye H; Zhang R; Zhang Z; Zhu X; Wilcox MH
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary.
    Das D; Tulkens PM; Mehra P; Fang E; Prokocimer P
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S51-7. PubMed ID: 24343833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.
    Prokocimer P; De Anda C; Fang E; Mehra P; Das A
    JAMA; 2013 Feb; 309(6):559-69. PubMed ID: 23403680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.
    Ong V; Flanagan S; Fang E; Dreskin HJ; Locke JB; Bartizal K; Prokocimer P
    Drug Metab Dispos; 2014 Aug; 42(8):1275-84. PubMed ID: 24875463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
    Rybak JM; Marx K; Martin CA
    Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of neuropathological changes in rats administered tedizolid phosphate for nine months.
    Schlosser MJ; Hosako H; Radovsky A; Butt MT; Draganov D; Vija J; Oleson F
    Antimicrob Agents Chemother; 2015 Jan; 59(1):475-81. PubMed ID: 25385101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate.
    Lodise TP; Drusano GL
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S28-34. PubMed ID: 24343829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections.
    Gras J
    Drugs Today (Barc); 2014 Nov; 50(11):729-37. PubMed ID: 25525633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections.
    Li D; Sabato PE; Guiastrennec B; Ouerdani A; Feng HP; Duval V; De Anda CS; Sears PS; Chou MZ; Hardalo C; Broyde N; Rizk ML
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0089521. PubMed ID: 34516243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tedizolid for treatment of acute bacterial skin and skin structure infections.
    Hui Y; Xiaoju L
    Expert Rev Anti Infect Ther; 2015; 13(9):1051-60. PubMed ID: 26211946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis.
    Park KH; Greenwood-Quaintance KE; Mandrekar J; Patel R
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6568-6572. PubMed ID: 27550347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Efficacy of Oral and/or Intravenous Tedizolid Phosphate From a Randomized Phase 3 Trial in Adolescents With Acute Bacterial Skin and Skin Structure Infections.
    Bradley JS; Antadze T; Ninov B; Tayob MS; Broyde N; Butterton JR; Chou MZ; De Anda CS; Kim JY; Sears PS
    Pediatr Infect Dis J; 2021 Mar; 40(3):238-244. PubMed ID: 33395210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tedizolid: A New Oxazolidinone Antibiotic for Skin and Soft Tissue Infections.
    Chahine EB; Sucher AJ; Knutsen SD
    Consult Pharm; 2015 Jul; 30(7):386-94. PubMed ID: 26173190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiolabeled Tedizolid Phosphate Liposomes for Topical Application: Design, Characterization, and Evaluation of Cellular Binding Capacity.
    Karpuz M; Atlihan-Gundogdu E; Demir ES; Senyigit Z
    AAPS PharmSciTech; 2021 Feb; 22(2):62. PubMed ID: 33528714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.
    O'Riordan W; Green S; Mehra P; De Anda C; Fang E; Prokocimer P
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S43-50. PubMed ID: 24343832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative In Vivo Efficacies of Tedizolid in Neutropenic versus Immunocompetent Murine Streptococcus pneumoniae Lung Infection Models.
    Abdelraouf K; Nicolau DP
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.